Patients

Giving patients a chance is what drives us. We are committed to developing safe and effective therapies for people suffering from a wide range of fibrotic diseases.

Pliant is currently targeting fibrotic diseases in a variety of organs and conditions, including the lung (IPF), liver (primary sclerosing cholangitis and NASH), kidney (renal fibrosis), skin (systemic sclerosis), muscle (Duchenne muscular dystrophy) and the gastrointestinal tract (intestinal fibrosis in inflammatory bowel disease).

With biomarker-based approaches, we aim to design efficient clinical trials leveraging validated clinical endpoints and potentially improve diagnosis, selection and assessment of treatments for IPF.

IPF Patient Registry and Biomarker Registry

We have dedicated our resources to building a robust patient registry. Through our collaborations with University of California, San Francisco and Stanford University, we are collecting clinical and laboratory data on patients with IPF. Our registry aims to expand knowledge of the natural progression of the disease and fuel biomarker discovery.

Despite significant study, no validated biomarkers currently exist for IPF. Our biomarker discovery efforts seek to identify and validate proteins or genes that can be used for early diagnosis, risk stratification, predicting response to therapy and monitoring response to therapy. Our scientists and research collaborators have successfully integrated tissue and plasma proteomics approaches to enhance detection of tissue-specific and circulating proteins related to fibrotic lung disease.

Clinical Trial Access

Pliant is currently conducting clinical research studies in IPF and PSC. INTEGRIS-IPF and INTEGRIS-PSC clinical research studies are actively enrolling eligible participants.

If you are interested in learning more about these clinical trials, email us at clinicaltrials@pliantrx.com

IPF is a chronic and progressive fibrotic disease in which lung tissue becomes thickened, stiff and scarred, leading to increased difficulty in breathing and decreased quality of life. As lung fibrosis progresses, it becomes increasingly difficult for the lungs to transfer oxygen into the bloodstream— ultimately preventing vital organs from receiving the oxygen necessary to function properly. IPF currently affects approximately 140,000 people in the U.S.

Primary Sclerosing Cholangitis (PSC) is a rare, long-term liver disease affecting the bile ducts (small tubes) inside and outside the liver. With PSC, the bile ducts become inflamed, making it harder for the bile to travel through. As a result, the bile builds up inside the liver. Over time this could lead to increased scarring of the liver and potentially liver failure, for which a liver transplant may be needed. Currently, there is no approved treatment for PSC. PSC affects approximately 30,000 people in the U.S.

IPF currently affects approximately

140,000

people in the U.S.

PSC currently affects approximately

30,000

people in the U.S.